Metis Global Partners LLC Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Metis Global Partners LLC boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 65.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,861 shares of the biopharmaceutical company's stock after buying an additional 14,124 shares during the period. Metis Global Partners LLC's holdings in Royalty Pharma were worth $915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Brooklyn Investment Group grew its stake in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 876 shares during the last quarter. Allworth Financial LP grew its stake in Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 877 shares during the last quarter. Fifth Third Bancorp grew its stake in Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 997 shares during the last quarter. Blue Trust Inc. grew its stake in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares during the last quarter. Finally, Spire Wealth Management grew its stake in Royalty Pharma by 377.6% during the 4th quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 1,699 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Royalty Pharma Stock Performance

Shares of RPRX traded down $0.27 during mid-day trading on Friday, reaching $33.01. The company had a trading volume of 5,407,966 shares, compared to its average volume of 4,474,442. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $19.03 billion, a P/E ratio of 22.77, a PEG ratio of 2.31 and a beta of 0.47. The stock has a 50 day moving average of $30.87 and a two-hundred day moving average of $28.39.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a $0.22 dividend. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.67%. Royalty Pharma's dividend payout ratio is presently 60.69%.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Royalty Pharma has a consensus rating of "Buy" and an average price target of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.